Company: DARE
Filing Date: 2025-04-24
Form Type: ARS
Source: 0001401914-25-000018
Chunk: 269

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: ARS
Chunk 269
---
30,161,391) Foreign currency translation adjustments (67,913) (9,585) Comprehensive loss $ (4,121,512) $ (30,170,976) Loss per common share - basic and diluted $ (0.48) $ (4.15) Weighted average number of common shares outstanding: Basic and diluted 8,497,459 7,275,308 See accompanying notes. F-5

Daré Bioscience, Inc. and Subsidiaries Consolidated Statements of Stockholders’ Equity (Deficit) Additional Accumulated other Total Common stock paid-in comprehensive Accumulated stockholders' Shares Amount capital loss deficit equity (deficit) Balance at December 31, 2022 7,068,790 $ 707 $ 152,537,354 $ (351,311) $ (141,074,640) $ 11,112,110 Stock-based compensation — — 2,530,684 — — 2,530,684 Issuance of common stock from the exercise of warrants 112,793 11 1,299,365 — — 1,299,376 Issuance of common stock, net of issuance costs 1,149,578 115 9,346,541 — — 9,346,656 Issuance of common stock warrants, net of issuance costs — — 834,510 — — 834,510 Net loss — — — — (30,161,391) (30,161,391) Foreign currency translation adjustments — — — (9,585) — (9,585) Balance at December 31, 2023 8,331,161 $ 833 $ 166,548,454 $ (360,896) $ (171,236,031) $ (5,047,640) Stock-based compensation — — 2,203,257 — — 2,203,257 Issuance cost on equity line paid in common stock 137,614 14 500,213 — — 500,227 Issuance of common stock, net of issuance costs 109,655 11 453,568 — — 453,579 Reverse stock split adjustment 121,956 12 (12) — Net loss — — — — (4,053,599) (4,053,599) Foreign currency translation adjustments — — — (67,913) — (67,913) Balance at December 31, 2024